Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Opioid pharmacogenetics of alcohol addiction.

Cold Spring Harbor perspectives in medicine - 1 Jul 2013

Berrettini Wade

Abstract excerpt

Alcohol addiction is one of the most common and devastating diseases in the world. Given the tremendous heterogeneity of alcohol-addicted individuals, it is unlikely that one medication will help nearly all patients. Thus, there is a clear need to develop predictors of response to existing medications. Naltrexone is a μ-opioid receptor antagonist, which has been approved in the United States for treatment of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alcoholism
Share to Clinical Trials as Topic
Share to Disease Models, Animal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation, Missense

Share to Naltrexone

Share to Polymorphism, Single Nucleotide

Share to Receptors, Opioid, mu

Source

Open in PubMed Open full text

Identifiers

PMID: 23729643
DOI: 10.1101/cshperspect.a012203
PMCID: PMC3685876

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Opioid pharmacogenetics of alcohol addiction.PMID 23729643Read ↗

Opioid neuroscience for addiction medicine: From animal models to FDA approval for alcohol addiction.Semantic proximity Read ↗

Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone.Semantic proximity Read ↗

A review of the existing pharmacogenomic literature of naltrexone for use in alcohol use disorder.Semantic proximity Read ↗

The μ-opioid receptor and treatment response to naltrexone.Semantic proximity Read ↗

Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics.Semantic proximity Read ↗

Pharmacogenetic treatments for drug addiction: alcohol and opiates.Semantic proximity Read ↗

Genetic polymorphisms and response to medications for alcohol use disorders: a systematic review and meta-analysis.Semantic proximity Read ↗

Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone.Semantic proximity Read ↗

Association of µ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis.Semantic proximity Read ↗

Pharmacogenetically driven treatments for alcoholism: are we there yet?Semantic proximity Read ↗

Pharmacogenetics of alcohol, nicotine and drug addiction treatments.Semantic proximity Read ↗

A Functional Polymorphism of the μ-Opioid Receptor Gene is Associated with Naltrexone Response in Alcohol-Dependent PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.